MedTrace Logo

Long Term Tapering or Standard Steroids for Nephrotic Syndrome

NCT00308321 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2007-11-29

No results posted yet for this study

Summary

Parallel group double blind randomised in patients with first episode corticosteroid sensitive nephrotic syndrome comparing time to relapse and adverse effects associated with a longer tapering steroid regimen with standard regime

Conditions

  • Nephrotic Syndrome

Interventions

DRUG

long term tapering of prednisolone

60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)

DRUG

standard prednisolone treatment

60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8

Sponsors & Collaborators

  • Institute of Child Health

    lead OTHER

Principal Investigators

  • Richard Trompeter · Great Ormond Street Hospital

  • Peter Houtman · Children's Hospital, Leicester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2008-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00308321 on ClinicalTrials.gov